Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Equity Average (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Equity Average for 10 consecutive years, with -$35.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 111.77% to -$35.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$35.4 million, a 111.77% decrease, with the full-year FY2025 number at $87.5 million, down 66.98% from a year prior.
  • Equity Average was -$35.4 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $80.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.1 billion in Q1 2021 to a low of -$35.4 million in Q4 2025.
  • A 5-year average of $442.5 million and a median of $293.6 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 384.77% in 2024, then plummeted 111.77% in 2025.
  • Ultragenyx Pharmaceutical's Equity Average stood at $928.1 million in 2021, then tumbled by 55.78% to $410.4 million in 2022, then plummeted by 62.63% to $153.4 million in 2023, then surged by 96.22% to $300.9 million in 2024, then crashed by 111.77% to -$35.4 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Equity Average are -$35.4 million (Q4 2025), $80.2 million (Q3 2025), and $147.8 million (Q2 2025).